ES2093248T3 - Metodos y composiciones para la supresion de la transformacion mediada por el neu. - Google Patents

Metodos y composiciones para la supresion de la transformacion mediada por el neu.

Info

Publication number
ES2093248T3
ES2093248T3 ES92902782T ES92902782T ES2093248T3 ES 2093248 T3 ES2093248 T3 ES 2093248T3 ES 92902782 T ES92902782 T ES 92902782T ES 92902782 T ES92902782 T ES 92902782T ES 2093248 T3 ES2093248 T3 ES 2093248T3
Authority
ES
Spain
Prior art keywords
gene
neu
products
suppression
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92902782T
Other languages
English (en)
Inventor
Mien-Chie Hung
Di-Hua Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Application granted granted Critical
Publication of ES2093248T3 publication Critical patent/ES2093248T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

SE PRESENTAN METODOS Y COMPOSICIONES PARA LA SUPRESION DE LA EXPESION DEL ONCOGENE "NEU" ASI COMO LA SUPRESION DE LA TRANSFORMACION, TUMORIGENESIS Y METASTASIS MEDIATIZADA POR EL ONCOGENE "NEU". EL METODO DESCUBIERTO COMPRENDE LA INTRODUCCION DE PRODUCTOS DEL GEN 1 A DEL ADENOVIRUS EN LAS CELULAS INFECTADAS. ESTOS PRODUCTOS, QUE SON PREFERIBLEMENTE INTRODUCIDOS MEDIANTE TRANSFECTACION DEL GEN E1A EN LAS CELULAS INFECTADAS, SIRVE PARA SUPRIMIR LA EXPRESION DEL GEN "NEU" SEGUN SE HA MEDIDO MEDIANTE UNA REDUCCION DE LA EXPRESION DEL P185. ADEMAS, LOS PRODUCTOS DEL GEN E1A SIRVEN PARA SUPRIMIR EL FENOTIPO ONCOGENICO, SEGUN SE INDICA POR LA REDUCCION EN EL CRECIMIENTO CELULAR, ASI COMO TUMORIGENICO Y METASTATICO POTENCIAL IN VIVO. LOS INVENTORES PROPONEN QUE LOS PRODUCTOS DEL GEN E1A, O SUS DERIVADOS, PUEDEN EMPLEARSE ULTIMAMENTE COMO MODALIDADES DE TRATAMIENTO PARA CANCERES MEDIATIZADOS POR EL ONCOGENE "NEU" TALES COMO LOS CANCERES DEL TRACTO GENITAL FEMENINO Y DE PULMON.
ES92902782T 1990-12-04 1991-12-04 Metodos y composiciones para la supresion de la transformacion mediada por el neu. Expired - Lifetime ES2093248T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62146590A 1990-12-04 1990-12-04

Publications (1)

Publication Number Publication Date
ES2093248T3 true ES2093248T3 (es) 1996-12-16

Family

ID=24490270

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92902782T Expired - Lifetime ES2093248T3 (es) 1990-12-04 1991-12-04 Metodos y composiciones para la supresion de la transformacion mediada por el neu.

Country Status (11)

Country Link
US (1) US5651964A (es)
EP (1) EP0560932B1 (es)
JP (2) JPH06504671A (es)
AT (1) ATE142261T1 (es)
AU (1) AU651650B2 (es)
CA (1) CA2096723C (es)
DE (1) DE69121903T2 (es)
DK (1) DK0560932T3 (es)
ES (1) ES2093248T3 (es)
GR (1) GR3021805T3 (es)
WO (1) WO1992010573A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US6861506B1 (en) 1996-01-11 2005-03-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
CA2250222A1 (en) 1996-03-20 1997-09-25 Mien-Chie Hung Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
WO2002053701A2 (en) * 2000-12-29 2002-07-11 Vanderbilt University Epididymal lipocalin gene and uses thereof
US20020169126A1 (en) * 2001-03-21 2002-11-14 Mien-Chie Hung Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
WO2006031210A1 (en) 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
CA2579574A1 (en) 2004-07-23 2007-01-04 The University Of North Carolina At Chapel Hill Methods and materials for determining pain sensitivity and predicting and treating related disorders
BRPI0906606A2 (pt) * 2008-01-31 2015-07-14 Univ Vanderbilt Tratamento terapêutico para condições do pulmão.
SG196863A1 (en) * 2008-01-31 2014-02-13 Univ Vanderbilt Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
WO1990015595A1 (en) * 1989-06-22 1990-12-27 Vestar, Inc. Encapsulation process
JP3534749B2 (ja) * 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy

Also Published As

Publication number Publication date
DE69121903T2 (de) 1997-04-10
AU9146991A (en) 1992-07-08
WO1992010573A1 (en) 1992-06-25
ATE142261T1 (de) 1996-09-15
JPH06504671A (ja) 1994-06-02
US5651964A (en) 1997-07-29
EP0560932B1 (en) 1996-09-04
DE69121903D1 (de) 1996-10-10
JP3323491B2 (ja) 2002-09-09
GR3021805T3 (en) 1997-02-28
DK0560932T3 (es) 1997-02-17
EP0560932A1 (en) 1993-09-22
CA2096723C (en) 2006-03-28
AU651650B2 (en) 1994-07-28
JP2002114707A (ja) 2002-04-16
CA2096723A1 (en) 1992-06-05

Similar Documents

Publication Publication Date Title
ES2093248T3 (es) Metodos y composiciones para la supresion de la transformacion mediada por el neu.
WO1995016051A3 (en) Methods and compositions for the suppression of neu mediated transformation
Christl et al. Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis
PH12019501792A1 (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
ATE302764T1 (de) Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes
Russo et al. Development pattern of human breast and susceptibility to carcinogenesis
EP3677266B1 (en) Exon 18 and/or exon 21 mutant egfr selective inhibitor
Timmons et al. Expression of galectin-7 during epithelial development coincides with the onset of stratification
Velcich et al. Altered phenotype of HT29 colonic adenocarcinoma cells following expression of the DCC gene
Shamloo et al. Dysregulation of adenosine kinase isoforms in breast cancer
Pályi et al. Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101)
Blagosklonny Cell immortality and hallmarks of cancer
IL147123A0 (en) Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
Russo et al. Ape1/Ref-1 expression and cellular localization in human thyroid carcinoma cell lines
Nishi et al. Stimulation of growth by both androgen and estrogen of the EMP-K1 transplantable tumor with androgen and estrogen receptors from human extramammary Paget's disease in nude mice
Nio et al. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-β1 in invasive ductal carcinoma of the pancreas
GB2004550A (en) Dibenzocycloocten-imines
MD503C2 (ro) Derivaţi ai pentapeptidelor
Romijn et al. Perspectives of the use of tissue culture methods as an alternative to human prostate cancer xenografts in nude mice
GB2378135A (en) Compositions derived from modiolus modiolus and methods for making and using same
RU2000101293A (ru) Производные бензо(5,6)циклогепта(1,2-в)пиридина для ингибирования фарнезил-протеин-трансферазы
MXPA03005004A (es) Metodos de diagnostico de cancer colorrectal y/o cancer de pecho, composiciones, y metodos para rastrear moduladores de cancer colorrectal y/o cancer de pecho.
SHIRAISHI et al. A CASE OF SIMULTANEOUS MALE BREAST AND ESOPHAGEAL CANCER
Koutsilieris Characterization of growth factors for osteoblasts from human prostatic tissue: implications for the pathogenesis of osteoblastic prostatic cancer metastases
Scheppach 16 Fermentation Profiles in the Gut and Functional Effects of Food Components

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 560932

Country of ref document: ES